Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
International Sweetene...International Sweetener Colloquium
Not Confirmed
Not Confirmed
22-25 February, 2026
Not Confirmed
Not Confirmed
23-25 February, 2026
Clinical Trial Supply ...Clinical Trial Supply Europe
Not Confirmed
Not Confirmed
24-25 February, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
International Sweetener Colloquium
Not Confirmed
Contact SupplierInternational Sweetener Colloquium
International Sweetene...International Sweetener Colloquium
Industry Trade Show
Not Confirmed
22-25 February, 2026
Industry Trade Show
Not Confirmed
23-25 February, 2026
Clinical Trial Supply ...Clinical Trial Supply Europe
Industry Trade Show
Not Confirmed
24-25 February, 2026
Digital content
NEWS #PharmaBuzz
18 Sep 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250917939293/en/Curatis-FDA-Minutes-Confirm-Positive-Outcome-of-Meeting-on-9.-September-2025-Corticorelin-on-Track-for-Phase-3
18 Sep 2025
// PHARMAWEB
https://www.pharmiweb.com/press-release/2025-09-18/fda-minutes-confirm-positive-outcome-of-meeting-on-9-september-2025-corticorelin-on-track-for-pha
15 Sep 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250914049177/en/Curatis-Double-Digit-Growth-in-Core-Business-and-Development-Milestone-Achieved-for-C-PTBE-01
05 Sep 2025
// PHARMAWEB
https://www.pharmiweb.com/press-release/2025-09-05/curatis-expands-distribution-business-with-phoenix-labs-with-up-to-chf-5m-additional-annual-revenues
31 Jul 2025
// PHARMAWEB
https://www.pharmiweb.com/press-release/2025-07-31/fda-confirms-type-b-meeting-on-corticorelin-pivotal-phase-3-study
23 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250522906458/en/Curatis-discloses-Corticorelin-as-active-substance-of-C-PTBE-01
Drugs in Development
Details:
Curatis is focusing its development activities for C-PTBE-01 on an very rare group of aggressive brain tumours (Diffuse Midline Glioma, DMG).
Lead Product(s): C-PTBE-01
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 14, 2024
Curatis Plans USA Biologic License for C-PTBE-01 to Extend Market Protection
Details : Curatis is focusing its development activities for C-PTBE-01 on an very rare group of aggressive brain tumours (Diffuse Midline Glioma, DMG).
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
November 14, 2024
Details:
Curatis is focusing its development activities for C-PTBE-01 on an extremely rare group of aggressive brain tumours (diffuse midline glioma) in children.
Lead Product(s): C-PBTE-01
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 27, 2024
Curatis Submits Orphan Drug Application in U.S. for Lead Candidate
Details : Curatis is focusing its development activities for C-PTBE-01 on an extremely rare group of aggressive brain tumours (diffuse midline glioma) in children.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 27, 2024
Details:
The agreement forms the basis for discussions on the introduction, development and commercialization of KIN001, a patented combination of two APIs, pamapimod and pioglitazone, for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in China.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: ChaoDian
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 10, 2023
Lead Product(s) : Pamapimod,Pioglitazone
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : ChaoDian
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement forms the basis for discussions on the introduction, development and commercialization of KIN001, a patented combination of two APIs, pamapimod and pioglitazone, for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in China.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 10, 2023
Details:
KIN001 is a patented combination of pamapimod, a highly selective investigational small molecule inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), and pioglitazone, a marketed drug for the treatment of type 2 diabetes.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 21, 2023
Lead Product(s) : Pamapimod,Pioglitazone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update
Details : KIN001 is a patented combination of pamapimod, a highly selective investigational small molecule inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), and pioglitazone, a marketed drug for the treatment of type 2 diabetes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 21, 2023
Details:
KIN001 is an orally administered combination of pamapimod and pioglitazone. Pamapimod is a p38 MAPK inhibitor, whereas pioglitazone is a PPAR gamma activator. It is currently being developed in COVID-19, Idiopathic Pulmonary Fibrosis and wet Age-Related Macular Degeneration.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 16, 2023
Lead Product(s) : Pamapimod,Pioglitazone
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KIN001 is an orally administered combination of pamapimod and pioglitazone. Pamapimod is a p38 MAPK inhibitor, whereas pioglitazone is a PPAR gamma activator. It is currently being developed in COVID-19, Idiopathic Pulmonary Fibrosis and wet Age-Related ...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 16, 2023
Details:
KIN001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Lead Product(s): KIN001
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 21, 2022
Lead Product(s) : KIN001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KIN001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 21, 2022
Details:
KIN001 is an orally available patented combination of pamapimod, a highly selective investigational small molecule inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), and pioglitazone, a marketed drug for the treatment of type 2 diabetes.
Lead Product(s): Pamapimod
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 06, 2022
Lead Product(s) : Pamapimod
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvaria...
Details : KIN001 is an orally available patented combination of pamapimod, a highly selective investigational small molecule inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), and pioglitazone, a marketed drug for the treatment of type 2 diabetes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 06, 2022
Details:
KIN001 is combination of two APIs: pamapimod and pioglitazone. Kinarus has found that combining pamapimod with pioglitazone, leads to synergistic efficacy and increased duration of action in preclinical models of wet AMD, IPF and fibrotic and inflammatory diseases.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 22, 2022
Lead Product(s) : Pamapimod,Pioglitazone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
Details : KIN001 is combination of two APIs: pamapimod and pioglitazone. Kinarus has found that combining pamapimod with pioglitazone, leads to synergistic efficacy and increased duration of action in preclinical models of wet AMD, IPF and fibrotic and inflammator...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 22, 2022
Details:
KIN001 is a patented combination of two active pharmaceutical ingredients (APIs): pamapimod and pioglitazone. Pamapimod is a highly selective clinical stage small molecule inhibitor of the p38 MAP kinase signaling pathway.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Great Health Companion Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 16, 2022
Lead Product(s) : Pamapimod,Pioglitazone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Great Health Companion Group
Deal Size : Undisclosed
Deal Type : Partnership
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
Details : KIN001 is a patented combination of two active pharmaceutical ingredients (APIs): pamapimod and pioglitazone. Pamapimod is a highly selective clinical stage small molecule inhibitor of the p38 MAP kinase signaling pathway.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 16, 2022
Details:
KIN001 is an orally administered combination of two drugs that have demonstrated synergistic antiviral and anti-inflammatory activity, as well as ability to reduce tissue fibrosis.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 29, 2022
Lead Product(s) : Pamapimod,Pioglitazone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Kinarus Therapeutics Initiates KIN001 Phase II KINFAST Clinical Trial in COVID-19 Outpatients
Details : KIN001 is an orally administered combination of two drugs that have demonstrated synergistic antiviral and anti-inflammatory activity, as well as ability to reduce tissue fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 29, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info : Allowed
Registration Country : Switzerland
Dosage Form : Solution For Injection
Brand Name : Emerade ug
Dosage Strength : 150mcg/5ml
Packaging :
Approval Date : 2021-11-23
Application Number : 67620
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Allowed
Registration Country : Switzerland
Dosage Form : Solution For Injection
Brand Name : Emerade ug
Dosage Strength : 300mcg/0.3ml
Packaging :
Approval Date : 2021-11-23
Application Number : 67620
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Allowed
Registration Country : Switzerland
Dosage Form : Injectable Solution
Brand Name : Emerade ug
Dosage Strength : 500mcg/0.5ml
Packaging :
Approval Date : 2021-11-23
Application Number : 67620
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Allowed
Registration Country : Switzerland
Dosage Form : Powder For Concentrate F...
Brand Name : Proleukin
Dosage Strength :
Packaging :
Approval Date : 12/09/1995
Application Number : 50581
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Allowed
Registration Country : Switzerland
Dosage Form : Film Coated Tablet
Brand Name : Renacet
Dosage Strength : 475mg
Packaging :
Approval Date : 27/02/2008
Application Number : 57591
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Allowed
Registration Country : Switzerland
Dosage Form : Film Coated Tablet
Brand Name : Renacet
Dosage Strength : 950mg
Packaging :
Approval Date : 27/02/2008
Application Number : 57591
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Allowed
Registration Country : Switzerland
Dosage Form : Oral Solution
Brand Name : Psychopax
Dosage Strength : 12.5mg/ml
Packaging :
Approval Date : 28/05/1984
Application Number : 44941
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Allowed
Registration Country : Switzerland
Dosage Form : Oral Solution
Brand Name : Effortil
Dosage Strength : 7.5mg/g
Packaging :
Approval Date : 18/09/1958
Application Number : 24199
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Allowed
Registration Country : Switzerland
Dosage Form : Tablet
Brand Name : Mysoline
Dosage Strength : 250mg
Packaging :
Approval Date : 15/10/1952
Application Number : 17885
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Allowed
Registration Country : Switzerland
Dosage Form : Patch
Brand Name : Garamycin
Dosage Strength : 50mg
Packaging :
Approval Date : 10/10/1996
Application Number : 52918
Regulatory Info : Allowed
Registration Country : Switzerland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
